A new Cedars Sinai Physician Associated Study used the processes and care of Daybreak to evaluate a dentist-led, ...
February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy ...
LISLE, IL, UNITED STATES, January 12, 2026 /EINPresswire.com/ -- OWP Pharmaceuticals today announced commercial product ...
The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...
Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is excited to ...
Considerable on MSN
Oral GLP-1 obesity drugs near wider access
The post Oral GLP-1 Obesity Drugs Near Wider Access appeared first on Considerable.
U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025Company ...
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback